P53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities.
Ontology highlight
ABSTRACT: Doxorubicin is a widely used chemotherapeutic agent that causes dose-dependent cardiotoxicity in a subset of treated patients, but the genetic determinants of this susceptibility are poorly understood. Here, we report that a noncanonical tumor suppressor activity of p53 prevents cardiac dysfunction in a mouse model induced by doxorubicin administered in divided low doses as in the clinics. While relatively preserved in wild-type (p53+/+ ) state, mice deficient in p53 (p53-/- ) developed left ventricular (LV) systolic dysfunction after doxorubicin treatment. This functional decline in p53-/- mice was associated with decreases in cardiac oxidative metabolism, mitochondrial mass, and mitochondrial genomic DNA (mtDNA) h
SUBMITTER: Li J
PROVIDER: S-EPMC6765288 | biostudies-literature | 2019 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA